DOI: https://doi.org/10.21203/rs.2.16194/v2
Background: Circular RNAs (circRNAs) are new stars in the network of noncoding RNAs and are regarded as key control factors in numerous tumours. The purpose of our study was to evaluate the clinical, prognostic and diagnostic role of circRNAs in colorectal cancer. The quality of all the articles were assessed by the Newcastle‐Ottawa Scale.
Methods: An online search in electronic databases, including the PubMed, Cochrane Library and Web of Science online databases, was conducted to identify as many relevant papers as possible. Nineteen relevant studies were enrolled in this meta-analysis, with seven on diagnosis, eight on prognosis and 11 on clinicopathological features.
Results: For the diagnostic value of circRNAs, the pooled results showed that the area under the curve (AUC) was 0.82 for identifying patients with colorectal cancer, with a sensitivity of 83% and a specificity of 72%. In terms of prognosis, carcinogenic circRNAs have a negative effect on overall survival (OS: HR = 2.29, 95% CI: 1.50-3.52), and increases in tumour suppressor circRNA expression are associated with longer survival (OS: HR = 0.37, 95% CI: 0.22-0.64). And the elevated expression of oncogenic circRNAs is associated with poor clinical features while tumor suppressor circRNAs are the complete opposite.
Conclusions: These results suggest that circRNAs may be a potential biomarker for the diagnosis and prognosis of colorectal cancer.
Circular RNAs (circRNAs), consisting of a circular configuration through a typical 5’ to 3’-phosphodiester bonds, are a novel class of endogenous noncoding RNAs[1-3]. CircRNAs play a special role as molecular markers in many human diseases including tumors, due to their conservation, abundance and tissue specificity[4]. In addition, circRNAs can be classified into four categories: exon circRNAs, intron circRNAs, exon-intron circRNAs, and intergenic circRNAs[5]. Different types of circRNAs have distinct functions, including interacting with RNA binding proteins, regulating the stability of the mRNAs, regulating gene transcription, sponging microRNAs and participating in translation[5-7]. However, the underlying mechanisms and functions of circRNAs remain uncertain.
Extensive studies have indicated that circRNAs play a major role in tumourigenesis, the development of cardiovascular diseases, and the pathogenesis of neurodegenerative diseases[8]. However, the differential expression of circRNAs and their definite functions are still not totally clear in human colorectal cancer (CRC). Colorectal cancer is among the most common malignancies of the digestive system and the fourth leading cause of cancer-related death worldwide[9]. Although considerable progress has been made in the diagnosis and treatment of this disease, the prognosis of CRC patients is still poor, due to the delay in early diagnosis and the high frequency of metastasis and recurrence[10]. In this study, we performed a meta-analysis and a comprehensive search of all relevant literature to summarize the diagnostic, prognostic and clinical significance of circRNAs in CRC patients.
Data search strategy
The PubMed, Cochrane Library, and Web of Science online databases were searched for studies on circRNA research that were published in English before May 15, 2019. The search strategy in this study included the following terms: (1)” circRNA” or “circular RNA” and (2) “colorectal cancer” or “colorectal carcinoma” or “colorectal tumour” or “CRC”. Two researchers (Yuan and Guo) assessed the title, abstract and full text to identify the appropriate articles. Other researchers (Li), together with the former two researchers were involved in the data extraction. Any disagreements were settled by a third researcher (Chen). Then, the data were extracted from the selected articles and populated it into a table.
Inclusion and exclusion criteria
This study used the following criteria when selecting articles. Studies that met the following inclusion criteria were included in the meta-analysis: (1) cohort study or case-control study; (2) patients with a pathological diagnosis of CRC; and (3) studies that detected the circRNA expression level and provided information on the clinicopathological features and prognosis of patients. Studies were excluded if the following excluded criteria were met: (1) not about circRNAs or CRC; (2) data similar to that in previous studies; (3) case reports, animal experiments, reviews, and so on; and (4) no applicable data.
Data extraction and quality assessment
Two investigators (Yuan and Guo) evaluated the eligibility of the studies and independently extracted the following data: (a) author, year of publication, circRNA type, cancer type, case number and detection method; (b) expression level of the circRNAs, follow-up time and overall survival (OS); (c) the sensitivity and specificity of the circRNAs for diagnosis; and (d) clinical data with age, gender, tumour size, TNM stage, differentiation, lymphatic metastasis, distal metastasis and so on[11]. The Newcastle‐Ottawa Scale (NOS; Supplementary Table S1) was adopted to evaluate the quality of the studies. The quality assessment of each included study was carried out by two independent investigators (Yuan and Guo). A third investigator (Li) discussed any differences. A study was considered high quality if the score was ≧7.
Statistical analysis
Statistical analysis was performed using STATA software (version 14). Pooled odds ratios (ORs) and 95% confidence intervals (CIs) were used to measure the clinicopathological parameters and hazard ratios (HRs) were used to assess the overall survival (OS). The number of true positive (TP), false positive (FP), false negative (FN) and true negative (TN) were calculated and finally the pooled sensitivity, specificity and the area under the ROC curve (AUC) were obtained to assess the diagnostic value of circRNAs. The chi-square test and I2 statistic were used to evaluate heterogeneity. When the I2 value was < 50%, no observable heterogeneity was suggested, and a fixed effects model was used [12]; otherwise, a random effects model was utilized. Sensitivity analysis was used to estimate the potential sources of heterogeneity. Qualitative evaluation of publication bias was conducted through funnel plots, and quantitative evaluation was conducted by Begg and Egger’s tests.
Search Results
As shown in Fig. 1, 83 relevant studies were obtained from the database. Among them, 46 were full-text reviews and 27 were abstract reviews. Then, 27 articles were excluded for the following reasons: 5 were not about circRNAs or CRC, 10 did not report relevant outcomes, 3 were review articles, 1 was animal data, and 8 had insufficient data. In summary, there were 19 studies[13-31] included in this study, with a total of 1307 patients, including 11 on clinical parameters, 8 on prognosis and 7 on diagnosis.
Study characteristics
The main features of this analysis are presented in Table 1 and Table 2. All studies were published between 2015 and 2019. The number of samples ranged from 40-204, and the follow-up time of patients ranged from 57 months to 123 months. As shown in Table 1, six circRNAs were identified as tumour promoters, and two circRNAs were identified as tumour suppressors. As shown in Table 2, seven articles with sensitivity, specificity, and AUC data were included for the diagnosis analysis. All studies were of great quality with the quality scores ranging from 7 to 8(Supplementary Table 1).
Clinicopathological parameters
The associations between circRNAs and the clinical features of CRC patients are shown in Table 3. There was a significant correlation between the increase in oncogenic circRNAs expression and poor clinical features(tumor size: OR=1.769, 95% CI: 1.097 -2.852 ; differentiation grade: OR=1.743, 95% CI: 1.032-2.946; TNM stage: OR=3.320, 95% CI: 1.529 -7.207; T classification: OR=3.410, 95% CI :2.088-5.567; lymph node metastasis: OR=3.357, 95% CI: 2.160-5.215; distal metastasis: OR = 4.338, 95% CI: 2.503-7.520).In addition, high expression of tumor-suppressor circRNAs were related to favorable clinical parameter (differentiation grade: OR=0.453 , 95%CI : 0.261-0.787; T classification: OR=0.553, 95%CI: 0.328-0.934; distal metastasis: OR =0.196, 95%CI: 0.077 -0.498 ). However, no notable differences were found in terms of age, gender, or tumor location.
Overall survival
As shown in Fig.2A, the elevated expression of oncogenic circRNAs was notably associated with a poor prognosis (OS: HR = 2.29, 95% Cl: 1.50–3.52, p < 0.001), and a fixed-effects model was used with no great heterogeneity (I² = 0.0%, p = 0.937). In addition, the low expression of tumour-suppressor circRNAs was related to shorter survival times (OS: HR = 0.37, 95% Cl: 0.22–0.64, p < 0.001). No great heterogeneity (I² = 0.0%, p = 0.525) was found, and a fixed-effects model was employed (Fig. 2B).
Diagnosis analysis
Fig. 3 provides the forest plot of the sensitivity and specificity of circRNAs. And the random-effects model was employed with high heterogeneity (I² = 76.15% and I2=48.29%). The pooled results showed a sensitivity of 0.83 (95% CI: 0.75-0.88) and a specificity of 0.72 (95% CI: 0.66-0.78). In addition, the summary receiver operator characteristic (SROC) curve (Fig. 4) was calculated and AUC was 0.82 (95% CI 0.78–0.85). Taken together, these results suggest that circRNAs have a good diagnostic accuracy for CRC.
Publication bias and sensitivity analysis
From the funnel plot, there was no evidence of publication bias in our study (Supplementary Figure 1). There was no obvious publication bias according to Begg's funnel plot (p = 0.213; Supplementary Figure 2) and Egger's test (p = 0.722; Supplementary Figure 3). The sensitivity analysis suggested that the results were not altered greatly when omitting studies one by one (Supplementary Figure 4). Furthermore, Deek’s funnel plot asymmetry test[32] showed no obvious publication bias(p=0.07) for the diagnosis analysis (Supplementary Figure 5).
Recently, many studies have focused on the significant role of circRNAs, whereas no relevant meta-analyses on circRNA expression in CRC have been performed. A total of 1307 cancer patients from nineteen eligible studies were collected and analysed in this study, including seven on diagnosis, eight on prognosis, and eleven on clinicopathological features. For clinical features, the high expression of oncogenic circRNAs was notably associated with worse clinical parameters, while tumour-suppress circRNAs showed the opposite associations. For prognostic value, higher expression levels of oncogenic circRNAs indicated a poor survival, while higher expression levels of tumour suppressor circRNAs indicated the opposite. In addition, the summarized results showed AUC of 0.82, with 83% sensitivity and 72% specificity for the diagnostic value of circRNAs in CRC patients.
Our current study observed a significant relationship between abnormal circRNA expression and its diagnostic value in CRC patients. Since the tumour tissues, plasma, and even cells from patients with aberrant expression of circRNAs can be easily detected, measurements can be performed conveniently and economically. Coupled with the structural stability of circRNAs, circRNAs are a promising biomarker in the diagnosis of CRC. Although sensitivity analysis showed no significant heterogeneity, more pertinent investigations are warranted to corroborate our findings.
In previous meta-analyses, only five meta-analyses[33-37] detected an association between the circRNAs and carcinoma. However, in the studies of Wang et al[33], Chen et al[34] and Li et al[35], only one study was included to investigate the relationship between the circRNAs and CRC. Li et al[36] and Ding et al[37] assessed the diagnostic value of circRNAs for human cancers, in which five articles were included to investigate the diagnostic value of circRNAs in CRC, whereas they failed to discuss the role of circRNAs in CRC patients. In the present study, we collected all the relevant articles published to date and performed a meta-analysis including nineteen articles with 1307 CRC patients. Furthermore, we detected the prognostic and diagnostic value of circRNA expression in CRC patients. Nonetheless, further large-scale studies are needed to confirm these results.
However, several limitations must be considered when interpreting the conclusions of this meta-analysis. First, since all patients included in the article were from China, this reduced the applicability of the results across different ethnicities and regions. Moreover, there was a limited number of articles for a subgroup analysis according to different circRNAs. Furthermore, a relatively small number of patients was included in this meta-analysis, so larger-scale studies would be necessary to verify the obtained results. Finally, several studies did not provide HRs with their 95% CIs in the article, so we needed to extract them from the Kaplan-Meier survival curve.
In summary, our study demonstrated a crucial relationship between the variant expression of circRNAs and the diagnosis, prognosis clinicopathological features in patients with CRC. Furthermore, circRNAs may be novel biomarkers and therapeutic targets for colorectal cancer.
OR: odds ratios; 95% CI: 95% confidence interval; HR: Hazard ratio; OS: Overall survival; circRNAs: circular RNAs; CRC: colorectal cancer; SROC: the summary receiver operator characteristic curve; AUC: the area under the curve.
Ethics approval and consent to participate
Not applicable.
Consent for publication
Not applicable.
Availability of data and materials
All data analyzed during this study are included in this published article.
Competing interests
The authors declare that there are no conflicts of interest that could be perceived as prejudicing the impartiality of the research reported.
Funding
None.
Authors’ contributions
Conceived and designed the experiments: JTC and XXL. Performed the experiments: JPY, DMG, XXL, CZZ and JTC. Analyzed the data: JPY and DMG. Contributed analysis tools/materials: JPY, DMG, XXL and JTC. Wrote the paper: JPY and DMG. All authors have read and approved the final manuscript.
Acknowledgements
We are grateful to all researchers of enrolled studies.
TABLE1 Main characteristics of studies for prognosis analysis.
|
circRNA expression |
|
||||||
Study |
Year |
CircRNA |
Cancer Type |
High |
Low |
Detection Method |
Regulation |
Follow-up (months) |
Zeng et al. |
2018 |
circHIPK3 |
CRC |
89 |
89 |
qRT-PCR |
Upregulated |
91 |
Fang et al. |
2018 |
circ_100290 |
CRC |
24 |
20 |
qRT-PCR |
Upregulated |
59 |
Weng et al. |
2017 |
circCiRS7 |
CRC |
89 |
76 |
qRT-PCR |
Upregulated |
123 |
Wang et al. |
2019 |
circPVT1 |
CRC |
32 |
32 |
qRT-PCR |
Upregulated |
58 |
Jin et al. |
2018 |
circ_0136666 |
CRC |
26 |
26 |
qRT-PCR |
Upregulated |
60 |
Wang et al. |
2018 |
circ_0071589 |
CRC |
20 |
20 |
qRT-PCR |
Upregulated |
58 |
Li et al. |
2018 |
circ_0000711 |
CRC |
50 |
51 |
qRT-PCR |
Downregulated |
60 |
Wang et al. |
2018 |
circ_0014717 |
CRC |
23 |
23 |
qRT-PCR |
Downregulated |
57 |
Note: CRC: colorectal cancer; qRT‐PCR: quantitative real time polymerase chain reaction.
TABLE2 Main characteristics of studies for diagnosis analysis.
|
Sample size |
|
Diagnosis power |
|||||||
Study |
Year |
CircRNA |
Cancer Type |
case |
control |
Method |
Regulation |
Sen. |
Spe. |
AUC. |
Ji et al. |
2018 |
circ_0001649 |
CRC |
64 |
64 |
qRT-PCR |
downregulated |
0.828 |
0.781 |
0.857 |
Li et al. |
2018 |
circITGA7 |
CRC |
69 |
48 |
qRT-PCR |
downregulated |
0.928 |
0.667 |
0.879 |
Wang et al. |
2017 |
circ_0000567 |
CRC |
102 |
102 |
qRT-PCR |
downregulated |
0.833 |
0.765 |
0.865 |
Zhuo et al. |
2017 |
circ_0003906 |
CRC |
122 |
40 |
qRT-PCR |
downregulated |
0.803 |
0.725 |
0.818 |
Ruan et al. |
2019 |
circ_0002138 |
CRC |
35 |
35 |
qRT-PCR |
downregulated |
0.629 |
0.743 |
0.725 |
Wang et al. |
2015 |
circ_001988 |
CRC |
31 |
31 |
qRT-PCR |
downregulated |
0.68 |
0.730 |
0.788 |
Li et al. |
2018 |
circ_0000711 |
CRC |
101 |
101 |
qRT-PCR |
downregulated |
0.910 |
0.58 |
0.810 |
Note: AUC: area under the ROC curve; qRT‐PCR: quantitative real‐time polymerase chain reaction; Sen: sensitivity; Spe.: specificity; CRC: colorectal cancer.
TABLE 3 Clinical Parameters of circRNAs in CRC.
|
Tumor promoter |
Tumor Suppressor |
||||
OR |
95%CI |
P |
OR |
95%CI |
P |
|
Age (older/younger) |
1.078 |
0.737-1.577 |
0.698 |
0.589 |
0.241-1.437 |
0.224 |
Gender (M/W) |
1.114 |
0.757-1.639 |
0.968 |
0.805 |
0.491-1.320 |
0.390 |
Tumor size (larger/smaller) |
1.769 |
1.097-2.852 |
0.019 |
0.658 |
0.382-1.132 |
0.131 |
Tumor location (rectum/colon) |
0.888 |
0.572-1.380 |
0.598 |
0.902 |
0.480-1.694 |
0.748 |
Differentiation grade (poor/well & moderate) |
1.743 |
1.032-2.946 |
0.038 |
0.453 |
0.261-0.787 |
0.005 |
TNM stage (III+IV/I+II) |
3.320 |
1.529-7.207 |
0.002 |
0.442 |
0.187-1.042 |
0.062 |
T classification (T3+T4/T1+T2) |
3.410 |
2.088-5.567 |
0.000 |
0.533 |
0.328-0.934 |
0.027 |
Lymph node metastasis (Y/N) |
3.357 |
2.160-5.215 |
0.000 |
0.389 |
0.116-1.307 |
0.127 |
Distant metastasis (Y/N) |
4.338 |
2.503-7.520 |
0.000 |
0.196 |
0.077-0.498 |
0.001 |
Note: CI: confidence interval; M: men; N: no; W: women; Y: yes; OR: odds ratio. The results are in bold if p < 0.05.